Literature DB >> 18317359

Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes.

Laszlo Markasz1, Henriette Skribek, Michael Uhlin, Rita Otvos, Emilie Flaberg, Staffan Eksborg, Eva Olah, Gyorgy Stuber, Laszlo Szekely.   

Abstract

Tumors are considered to be possible targets of immunotherapy using stimulated and expanded cytotoxic T-lymphocytes (CTL). It is important to consider the drug-induced effects when chemotherapeutic regimens and CTL-mediated immunotherapy is planned to be used in parallel. In this study, we characterized the effect of 29 frequently used chemotherapeutic agents on the cytotoxic activity of autologous and allogeneic CTLs. We found that treatment of CTLs with the following drugs: docetaxel, vincristine, chlorambucil, mitomycin C, oxaliplatin, doxorubicin, and bleomycin effectively inhibited CTL-mediated killing, without affecting their viability. On the other hand, the following drugs enhanced or permitted efficient CTL-mediated killing in vitro at concentrations comparable with the maximally achieved therapeutic concentration in vivo in humans: daunorubicin, prednisolone, vinorelbine, cisplatin, methotrexate, hydroxyurea, cytarabine, cyclophosphamide, topotecan, epirubicin, fluorouracil, carboplatin, asparaginase, 6-mercaptopurine, and bortezomib. Our results could potentially be used in the future to design new CTL-based adjuvant immunotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317359     DOI: 10.1097/CJI.0b013e3181628b76

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  17 in total

Review 1.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.

Authors:  Mohammad A Shahshahan; Maureen N Beckley; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2011-08-23       Impact factor: 6.166

3.  Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.

Authors:  P Schroeder; C Lindemann; K Dettmar; J Brieger; J Gosepath; B Pogorzelski; D Seimetz; J Atz
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

4.  A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect.

Authors:  Andrea Nicolini; Massimo Conte; Giuseppe Rossi; Paola Ferrari; Angelo Carpi; Paolo Miccoli
Journal:  Tumour Biol       Date:  2010-06-30

5.  Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.

Authors:  Shabaz Sultan; Mark A J Gorris; I Jolanda M de Vries; Niven Mehra; Sandra van Wilpe; Diederik M Somford; Heidi V N Kusters-Vandevelde; Rutger H T Koornstra; Winald R Gerritsen; Michiel Simons; Antoine G van der Heijden
Journal:  Cancer Immunol Immunother       Date:  2022-06-30       Impact factor: 6.968

Review 6.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

Review 7.  Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.

Authors:  Tianqian Zhang; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-10-17       Impact factor: 6.968

8.  Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.

Authors:  Rui Deng; Hai Yi; Yi-Lan Liu; Fang-Yi Fan; L I Fu; Ye-Cheng Li; Guo-Shun Li; Si-Han Lai; Xiao-Juan Miao; Yan-Rong Shuai; Guang-Cui He; Y I Wang; Yan Zeng; Hao-Ping Sun; Ling Qiu; Y I Su
Journal:  Mol Clin Oncol       Date:  2015-09-16

Review 9.  Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.

Authors:  Andreas R de Biasi; Jonathan Villena-Vargas; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2014-09-09       Impact factor: 12.531

10.  Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.

Authors:  Cynthia A Wenner; Mark R Martzen; Hailing Lu; Michael R Verneris; Hongbo Wang; Joel W Slaton
Journal:  Int J Oncol       Date:  2011-12-12       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.